Certainly the improved survival of mice in the RCH-ACV experimental ALL in vivo model suggests that such a use would be beneficial, increasing the pool of patients that might benefit from development of CD123-specific CAR T cell therapy. The gene discussed is IL3RA; the disease is acute lymphoblastic leukemia.